The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter, phase II study of trastuzumab plus capecitabine and oxaliplatin (XELOX) as first-line chemotherapy for HER2-positive advanced gastric cancer: Update results of efficacy and toxicity.
Jifang Gong
No relevant relationships to disclose
Tianshu Liu
No relevant relationships to disclose
Qingxia Fan
No relevant relationships to disclose
Li Bai
No relevant relationships to disclose
Feng Bi
No relevant relationships to disclose
Shukui Qin
No relevant relationships to disclose
Jinwan Wang
No relevant relationships to disclose
Nong Xu
No relevant relationships to disclose
Ying Cheng
No relevant relationships to disclose
Yuxian Bai
No relevant relationships to disclose
Wei Liu
No relevant relationships to disclose
Liwei Wang
No relevant relationships to disclose
Lin Shen
No relevant relationships to disclose